Balance Sheet PressureThe balance sheet is under pressure, impacting potential for recovery.
Earnings OutlookFor FY25, DOCM expects sales growth of over 10% and adjusted EBITDA of minus CHF 35 to minus CHF 55m, which appears cautious compared to consensus expectations.
Market Share ConcernsThe outlook remains highly uncertain and could result in peer RDC gaining further share in the Germany Rx market as the rollout of ePrescription continues.